ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 237 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $881,532 | -35.9% | 42,300 | -26.3% | 0.01% | -30.8% |
| Q2 2023 | $1,374,730 | +93.8% | 57,400 | +52.3% | 0.01% | +85.7% |
| Q1 2023 | $709,514 | +51.6% | 37,700 | +28.2% | 0.01% | +40.0% |
| Q4 2022 | $468,048 | -15.1% | 29,400 | -12.8% | 0.01% | -16.7% |
| Q3 2022 | $551,332 | -36.0% | 33,700 | -5.3% | 0.01% | -25.0% |
| Q1 2022 | $862,000 | -1.8% | 35,600 | -5.3% | 0.01% | +33.3% |
| Q4 2021 | $878,000 | +41.4% | 37,600 | +0.5% | 0.01% | 0.0% |
| Q3 2021 | $621,000 | -17.1% | 37,400 | +21.8% | 0.01% | -14.3% |
| Q2 2021 | $749,000 | +103.0% | 30,700 | +114.7% | 0.01% | +75.0% |
| Q1 2021 | $369,000 | -45.3% | 14,300 | +13.5% | 0.00% | -42.9% |
| Q4 2020 | $674,000 | -41.0% | 12,600 | -54.5% | 0.01% | -46.2% |
| Q3 2020 | $1,143,000 | -23.2% | 27,700 | -9.8% | 0.01% | -27.8% |
| Q2 2020 | $1,488,000 | +28.5% | 30,700 | +12.0% | 0.02% | +12.5% |
| Q1 2020 | $1,158,000 | +316.5% | 27,400 | +321.5% | 0.02% | +433.3% |
| Q4 2019 | $278,000 | – | 6,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 28,439,114 | $590,396,000 | 3.89% |
| GREAT POINT PARTNERS LLC | 1,196,098 | $24,831,000 | 3.87% |
| EMORY UNIVERSITY | 196,601 | $4,081,000 | 2.67% |
| Ghost Tree Capital, LLC | 500,000 | $10,380,000 | 2.21% |
| Ghost Tree Capital, LLC | 500,000 | $10,380,000 | 2.21% |
| NEXTHERA CAPITAL LP | 500,000 | $10,380,000 | 1.99% |
| Palo Alto Investors LP | 1,684,180 | $34,964,000 | 1.41% |
| Opus Point Partners Management, LLC | 20,828 | $432,000 | 1.03% |
| Opaleye Management Inc. | 195,000 | $4,048,000 | 1.03% |
| GARRISON BRADFORD & ASSOCIATES INC | 48,500 | $1,007,000 | 0.81% |